Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke

Qian Li, Yuanshao Lin, Wensi Huang, Yulei Zhou, Xiaoli Chen, Brian Wang, Wanli Zhang, Zhengyi Cai, Jie Xue, Wenhui Zhang, Tieer Yu, Hong Wang, Jincai He, Kunlin Jin, Bei Shao

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

ABSTRACT: Interleukin-33 (IL-33), a newly recognized IL-1 family member, is expressed in various tissues and cells, and involved in pathogenesis of many human diseases. For example, IL-33 plays a protective role in cardiovascular diseases. However, the role of IL-33 in acute ischemic stroke (AIS) remains unclear. This study aims to investigate whether IL-33 level in AIS patient serum can be used as a potential diagnostic and prognostic marker. The study included two hundred and six patients with first-ever ischemic stroke, who were admitted within 72 hours after stroke onset. The serum level of IL-33 was measured with ELISA and the severity of AIS patients on admission was evaluated based on the National Institutes of Health Stroke Scale (NIHSS) score. The functional outcome at 3 months was determined using the Barthel index (BI). We found that serum IL-33 was significantly higher (P < 0.001) in patients with AIS [57.68 ng/L (IQR, 44.95-76.73)] compared with healthy controls [47.48 ng/L (IQR, 38.67-53.78)]. IL-33 was an independent diagnostic biomarker for AIS with an OR of 1.051 (95%Cl, 1.018-1.085; P=0.002). Serum IL-33 was higher (P < 0.05) in the stroke patients with small cerebral infarction volume compared to AIS patients with large cerebral infarction. In addition, serum IL-33 was also significantly higher (P = 0.001) in the patients with mild stroke, compared to the patients with severe stroke. Furthermore, serum IL-33 level in AIS patients with a worse outcome was higher (P < 0.001) compared to AIS patients with a better outcome. IL-33 was also an independent predictor for the functional outcome with an adjusted OR of 0.932 (95% CI, 0.882-0.986). Our results suggest that the lower level of serum IL-33 is associated with large infarction volume and greater stroke severity in AIS patients. Thus, IL-33 can be used as a novel and independent diagnostic and predicting prognostic marker in AIS.

Original languageEnglish
Pages (from-to)614-622
Number of pages9
JournalAging and Disease
Volume7
Issue number5
DOIs
StatePublished - 1 Jan 2016

Fingerprint

Biomarkers
Stroke
Serum
Interleukin-33
Cerebral Infarction
Patient Admission
National Institutes of Health (U.S.)
Interleukin-1
Stroke Volume
Infarction
Cardiovascular Diseases
Enzyme-Linked Immunosorbent Assay

Keywords

  • Acute ischemic stroke
  • Biomarker
  • Diagnosis
  • Interleukin-33
  • Outcome

Cite this

Li, Q., Lin, Y., Huang, W., Zhou, Y., Chen, X., Wang, B., ... Shao, B. (2016). Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke. Aging and Disease, 7(5), 614-622. https://doi.org/10.14336/AD.2016.0207
Li, Qian ; Lin, Yuanshao ; Huang, Wensi ; Zhou, Yulei ; Chen, Xiaoli ; Wang, Brian ; Zhang, Wanli ; Cai, Zhengyi ; Xue, Jie ; Zhang, Wenhui ; Yu, Tieer ; Wang, Hong ; He, Jincai ; Jin, Kunlin ; Shao, Bei. / Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke. In: Aging and Disease. 2016 ; Vol. 7, No. 5. pp. 614-622.
@article{61572842b74a463985070a30ba32f27a,
title = "Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke",
abstract = "ABSTRACT: Interleukin-33 (IL-33), a newly recognized IL-1 family member, is expressed in various tissues and cells, and involved in pathogenesis of many human diseases. For example, IL-33 plays a protective role in cardiovascular diseases. However, the role of IL-33 in acute ischemic stroke (AIS) remains unclear. This study aims to investigate whether IL-33 level in AIS patient serum can be used as a potential diagnostic and prognostic marker. The study included two hundred and six patients with first-ever ischemic stroke, who were admitted within 72 hours after stroke onset. The serum level of IL-33 was measured with ELISA and the severity of AIS patients on admission was evaluated based on the National Institutes of Health Stroke Scale (NIHSS) score. The functional outcome at 3 months was determined using the Barthel index (BI). We found that serum IL-33 was significantly higher (P < 0.001) in patients with AIS [57.68 ng/L (IQR, 44.95-76.73)] compared with healthy controls [47.48 ng/L (IQR, 38.67-53.78)]. IL-33 was an independent diagnostic biomarker for AIS with an OR of 1.051 (95{\%}Cl, 1.018-1.085; P=0.002). Serum IL-33 was higher (P < 0.05) in the stroke patients with small cerebral infarction volume compared to AIS patients with large cerebral infarction. In addition, serum IL-33 was also significantly higher (P = 0.001) in the patients with mild stroke, compared to the patients with severe stroke. Furthermore, serum IL-33 level in AIS patients with a worse outcome was higher (P < 0.001) compared to AIS patients with a better outcome. IL-33 was also an independent predictor for the functional outcome with an adjusted OR of 0.932 (95{\%} CI, 0.882-0.986). Our results suggest that the lower level of serum IL-33 is associated with large infarction volume and greater stroke severity in AIS patients. Thus, IL-33 can be used as a novel and independent diagnostic and predicting prognostic marker in AIS.",
keywords = "Acute ischemic stroke, Biomarker, Diagnosis, Interleukin-33, Outcome",
author = "Qian Li and Yuanshao Lin and Wensi Huang and Yulei Zhou and Xiaoli Chen and Brian Wang and Wanli Zhang and Zhengyi Cai and Jie Xue and Wenhui Zhang and Tieer Yu and Hong Wang and Jincai He and Kunlin Jin and Bei Shao",
year = "2016",
month = "1",
day = "1",
doi = "10.14336/AD.2016.0207",
language = "English",
volume = "7",
pages = "614--622",
journal = "Aging and Disease",
issn = "2152-5250",
publisher = "International Society on Aging and Disease",
number = "5",

}

Li, Q, Lin, Y, Huang, W, Zhou, Y, Chen, X, Wang, B, Zhang, W, Cai, Z, Xue, J, Zhang, W, Yu, T, Wang, H, He, J, Jin, K & Shao, B 2016, 'Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke', Aging and Disease, vol. 7, no. 5, pp. 614-622. https://doi.org/10.14336/AD.2016.0207

Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke. / Li, Qian; Lin, Yuanshao; Huang, Wensi; Zhou, Yulei; Chen, Xiaoli; Wang, Brian; Zhang, Wanli; Cai, Zhengyi; Xue, Jie; Zhang, Wenhui; Yu, Tieer; Wang, Hong; He, Jincai; Jin, Kunlin; Shao, Bei.

In: Aging and Disease, Vol. 7, No. 5, 01.01.2016, p. 614-622.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Serum IL-33 is a novel diagnostic and prognostic biomarker in acute ischemic stroke

AU - Li, Qian

AU - Lin, Yuanshao

AU - Huang, Wensi

AU - Zhou, Yulei

AU - Chen, Xiaoli

AU - Wang, Brian

AU - Zhang, Wanli

AU - Cai, Zhengyi

AU - Xue, Jie

AU - Zhang, Wenhui

AU - Yu, Tieer

AU - Wang, Hong

AU - He, Jincai

AU - Jin, Kunlin

AU - Shao, Bei

PY - 2016/1/1

Y1 - 2016/1/1

N2 - ABSTRACT: Interleukin-33 (IL-33), a newly recognized IL-1 family member, is expressed in various tissues and cells, and involved in pathogenesis of many human diseases. For example, IL-33 plays a protective role in cardiovascular diseases. However, the role of IL-33 in acute ischemic stroke (AIS) remains unclear. This study aims to investigate whether IL-33 level in AIS patient serum can be used as a potential diagnostic and prognostic marker. The study included two hundred and six patients with first-ever ischemic stroke, who were admitted within 72 hours after stroke onset. The serum level of IL-33 was measured with ELISA and the severity of AIS patients on admission was evaluated based on the National Institutes of Health Stroke Scale (NIHSS) score. The functional outcome at 3 months was determined using the Barthel index (BI). We found that serum IL-33 was significantly higher (P < 0.001) in patients with AIS [57.68 ng/L (IQR, 44.95-76.73)] compared with healthy controls [47.48 ng/L (IQR, 38.67-53.78)]. IL-33 was an independent diagnostic biomarker for AIS with an OR of 1.051 (95%Cl, 1.018-1.085; P=0.002). Serum IL-33 was higher (P < 0.05) in the stroke patients with small cerebral infarction volume compared to AIS patients with large cerebral infarction. In addition, serum IL-33 was also significantly higher (P = 0.001) in the patients with mild stroke, compared to the patients with severe stroke. Furthermore, serum IL-33 level in AIS patients with a worse outcome was higher (P < 0.001) compared to AIS patients with a better outcome. IL-33 was also an independent predictor for the functional outcome with an adjusted OR of 0.932 (95% CI, 0.882-0.986). Our results suggest that the lower level of serum IL-33 is associated with large infarction volume and greater stroke severity in AIS patients. Thus, IL-33 can be used as a novel and independent diagnostic and predicting prognostic marker in AIS.

AB - ABSTRACT: Interleukin-33 (IL-33), a newly recognized IL-1 family member, is expressed in various tissues and cells, and involved in pathogenesis of many human diseases. For example, IL-33 plays a protective role in cardiovascular diseases. However, the role of IL-33 in acute ischemic stroke (AIS) remains unclear. This study aims to investigate whether IL-33 level in AIS patient serum can be used as a potential diagnostic and prognostic marker. The study included two hundred and six patients with first-ever ischemic stroke, who were admitted within 72 hours after stroke onset. The serum level of IL-33 was measured with ELISA and the severity of AIS patients on admission was evaluated based on the National Institutes of Health Stroke Scale (NIHSS) score. The functional outcome at 3 months was determined using the Barthel index (BI). We found that serum IL-33 was significantly higher (P < 0.001) in patients with AIS [57.68 ng/L (IQR, 44.95-76.73)] compared with healthy controls [47.48 ng/L (IQR, 38.67-53.78)]. IL-33 was an independent diagnostic biomarker for AIS with an OR of 1.051 (95%Cl, 1.018-1.085; P=0.002). Serum IL-33 was higher (P < 0.05) in the stroke patients with small cerebral infarction volume compared to AIS patients with large cerebral infarction. In addition, serum IL-33 was also significantly higher (P = 0.001) in the patients with mild stroke, compared to the patients with severe stroke. Furthermore, serum IL-33 level in AIS patients with a worse outcome was higher (P < 0.001) compared to AIS patients with a better outcome. IL-33 was also an independent predictor for the functional outcome with an adjusted OR of 0.932 (95% CI, 0.882-0.986). Our results suggest that the lower level of serum IL-33 is associated with large infarction volume and greater stroke severity in AIS patients. Thus, IL-33 can be used as a novel and independent diagnostic and predicting prognostic marker in AIS.

KW - Acute ischemic stroke

KW - Biomarker

KW - Diagnosis

KW - Interleukin-33

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=85006511778&partnerID=8YFLogxK

U2 - 10.14336/AD.2016.0207

DO - 10.14336/AD.2016.0207

M3 - Article

AN - SCOPUS:85006511778

VL - 7

SP - 614

EP - 622

JO - Aging and Disease

JF - Aging and Disease

SN - 2152-5250

IS - 5

ER -